Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

KALA Company Profile and Key Details

NASDAQ : KALA

Kala Pharmaceuticals, Inc.

$6.64
-0.2-2.92%
At Close 4:00 PM
63.26
BESG ScoreESG Rating

KALA Stock Price Chart

Stock Price Today

Kala Pharmaceuticals, Inc. (KALA) stock declined over -2.92%, trading at $6.64 on NASDAQ, down from the previous close of $6.84. The stock opened at $6.95, fluctuating between $6.57 and $6.95 in the recent session.

Stock Snapshot

6.84
Prev. Close
6.95
Open
40.45M
Market Cap
6.09M
Number of Shares
6.565
Day Low
6.95
Day High
-0.57
P/E Ratio
82.24%
Free Float in %
-11.67
EPS (TTM)
2.77
Book Value
-10.52
Cash Flow per Share
31.17K
Volume

Stock Price History Chart

DateOpenHighLowCloseVolume
Feb 21, 20256.956.956.556.6431.14K
Feb 20, 20256.806.996.506.8432.35K
Feb 19, 20257.257.616.616.77112.44K
Feb 18, 20258.388.387.217.22154.72K
Feb 14, 20257.848.657.718.3873.72K
Feb 13, 20257.407.867.017.76104.58K
Feb 12, 20258.028.996.977.44610.49K
Feb 11, 202510.0710.8810.0010.88113.72K
Feb 10, 202511.2011.209.8310.3062.74K
Feb 07, 202510.4811.2010.4811.0292.2K
Feb 06, 20259.5510.799.5510.7383.17K
Feb 05, 20259.159.809.159.7077.72K
Feb 04, 20259.259.669.259.3024.1K
Feb 03, 20259.079.409.009.2241.03K
Jan 31, 20259.579.598.879.20188.1K
Jan 30, 20258.859.748.349.4869K
Jan 29, 20258.708.908.348.8329.5K
Jan 28, 20258.358.958.048.7773.1K
Jan 27, 20258.008.447.848.37112.51K
Jan 24, 20258.258.307.928.1160.93K

Contact Details

Arlington, MA 02476

United States

Website: https://www.kalarx.comContact: 781 996 5252

About Company

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Company Information

Employees43
Beta-2.04
Sales or Revenue$0.00
5Y Sales Change%0%
Fiscal Year EndsDecember
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Frequently Asked Questions

What is the current Kala Pharmaceuticals, Inc. (KALA) stock price?

Kala Pharmaceuticals, Inc. (NASDAQ: KALA) stock price is $6.64 in the last trading session. During the trading session, KALA stock reached the peak price of $6.95 while $6.57 was the lowest point it dropped to. The percentage change in KALA stock occurred in the recent session was -2.92% while the dollar amount for the price change in KALA stock was -$0.20.

KALA's industry and sector of operation?

The NASDAQ listed KALA is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Kala Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KALA?

Mr. Mark T. Iwicki
Chairman & Chief Executive Officer
Ms. Michele LaRussa
Senior Vice President of Regulatory Affairs & Quality Assurance
Mr. Darius Kharabi J.D., M.B.A.
Chief Bus. Officer
Ms. Mary Reumuth C.P.A., CPA
Chief Financial Officer & Treasurer
Ms. Jill S. Steier
Executive Director of Investor Relations & Corporation Communications
Ms. Mary Reumuth CPA, CPA
Chief Financial Officer & Treasurer
Mr. James Patnoe
Senior Vice President of Market Access, Commercial Operations & Pricing
Dr. Kim Brazzell Ph.D.
Head of R&D and Chief Medical Officer
Mr. Eric L. Trachtenberg
Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Dr. Justin Hanes Ph.D.
Founder & Chair of the Scientific Advisory Board
Mr. Vincent Kosewski
Senior Vice President of Manufacturing & Supply Chain Management
Mr. Todd Bazemore
Pres & Chief Operating Officer

How KALA did perform over past 52-week?

KALA's closing price is 57.72% higher than its 52-week low of $4.21 where as its distance from 52-week high of $11.20 is -40.71%.

How many employees does KALA have?

Number of KALA employees currently stands at 43.

Link for KALA official website?

Official Website of KALA is: https://www.kalarx.com

How do I contact KALA?

KALA could be contacted at phone 781 996 5252 and can also be accessed through its website. KALA operates from 1167 Massachusetts Avenue, Arlington, MA 02476, United States.

How many shares of KALA are traded daily?

KALA stock volume for the day was 31.17K shares. The average number of KALA shares traded daily for last 3 months was 64.14K.

What is the market cap of KALA currently?

The market value of KALA currently stands at $40.45M with its latest stock price at $6.64 and 6.09M of its shares outstanding.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph